In the management of HIV,

TIMES ARE CHANGING

Are your treatment decisions changing with them?

Now is the time to move to a 2-drug regimen (2DR) for your suppressed patients.

JULUCA' (dolutegravir/rilpivirine) is indicated for HIV-1 virologically suppressed adults on a stable regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

JULUCA' (dolutegravir/rilpivirine) is indicated for HIV-1 virologically suppressed adults on a stable regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

 

Do patients still need 3 drug regimens for life?

2DR: Meeting a clinical need

The HIV treatment landscape has changed dramatically over the past 30 years, with each decade serving as a foundation for the next to build upon. Today marks the beginning of the next era in HIV therapy...THE 2DR ERA.

Timeline

 

 

 

 

With DTG at the core, this now allows us to challenge the 20-year convention of 3-drug regimens.

 

The majority of time on therapy is spent maintaining virological suppression

 

A treatment plan that switches patients to a 2 drug regimen following virological suppression creates opportunities to:

 

 

 

Reduce the number of ARVs in your virologically suppressed patients, whilst maintaining the level of efficacy seen with 3-drug regimens5

Reduce ARV exposure and associated potential toxicities6-8

 

 

 

 

 

Why should patients take more ARVs than they need?

 

 

JULUCA is indicated for HIV-1 virologically suppressed adults on a stable regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

JULUCA is indicated for HIV-1 virologically suppressed adults on a stable regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.

 

See how a 2DR can benefit your patients

Is it time to switch your patients to a 2 drug regimen?

Question 1:

Would any of your HIV virologically suppressed patients be open to changing their current regimens to...

Findings from Positive Perspectives—a recent global survey of over 1,000 PLHIV—showed that:

 

of global participants were open to changing their current regimens to ones composed of fewer drugs as long as their viral load remained suppressed.9

Findings from Positive Perspectives—a recent global survey of over 1,000 PLHIV—showed that:

 

of global participants were open to changing their current regimens to ones composed of fewer drugs as long as their viral load remained suppressed.9

Question 2:

Do your patients ever raise concerns about the long-term effects of their HIV medication?

Findings from Positive Perspectives—a recent global survey of over 1,000 PLHIV—showed that:

 

of patients sometimes worried about long-term effects, with 67% raising concerns with their HCPs.9

Findings from Positive Perspectives—a recent global survey of over 1,000 PLHIV—showed that:

 

of patients sometimes worried about long-term effects, with 67% raising concerns with their HCPs.9

What makes dolutegravir' an ideal core agent to power a 2DR?

Click each icon for more information

DDIs=drug-drug interactions.

References:

  1. A timeline of HIV/AIDS. https://files.hive.gov/s3fs-public/aidsgov-timeline.pdf. Accessed November 7, 2017.
  2. Llibre JM, Walmsley S, Gatell JM. Backbones versus core agents in initial ART regimens: one game, two players. J Antimicrob Chemother. 2016;71:856-861.
  3. FDA-approved HIV medicines. https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/21/58/fda-approved-hiv-medicines. Updated August 17, 2017. Accessed November 7, 2017.
  4. ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV [news release]. London, UK; ViiV Healthcare group of companies; May 21, 2018. https://www.viivhealthcare.com/media/press-releases/2018/may/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv.aspx. Accessed May 24, 2018.
  5. Llibre JM, Hung C-C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018. doi:10.1016/s0140-6736(17)33095-7. 
  6. Carrero-Gras A, Antela A, Muñoz-Rodríguez J, et al. Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study. J Int AIDS Soc. 2014;17(4 suppl 3):19819.
  7. Carr A, Cooper DA. Adverse events of antiretroviral therapy. Lancet. 2000;356:1423-14­30.
  8. Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016;18:50-56.
  9. Young B, Spire B, Garcia D, et al. Patient experience and views on antiretroviral treatment: findings from the Positive Perspectives study. Presented at: IDWeek 2017; October 4-8, 2017; San Diego, CA. Poster 1393.
  10. Walmsley S, Baumgarten A, Berenguer J, et al. Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70(5):515-519.
  11. Molina J-M, Clotet B, van Lunzen J, et al; on behalf of the FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127-e136.
  12. Orrell C, Hagins DP, Belonosova E, et al. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Published online July 17, 2017. Lancet HIV. doi:10.1016/S2352-3018(17)30095-4.
  13. Aboud M, Kaplan R, Lombaard J, et al. Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment—interim data from the DAWNING Study. Presented at: Annual International AIDS Conference; July 23-26, 2017; Paris, France. Abstract TUAB0105LB.
  14. Cahn P, Pozniak AL, Mingrone H, et al; on behalf of the extended SAILING Study Team. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700-708.
  15. Raffi F, Jaeger H, Quiros-Roldan E, et al; on behalf of the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-935.
  16. TIVICAY (dolutegravir) Summary of Product Characteristics. March 2018.
  17. University of Liverpool. Drug interactions chart. February 2018. www.hiv-druginteractions.org. Accessed March 6, 2018.

UK/DTGRPV/0033/18(2) September 2018